Payment overview · 2025
General Payments
$383.73
21 reported records · 10 companies
Healthcare provider profile · identity verified
Santsaran C Patel, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SIERRA VISTA, AZ · NPI 1316960016
Verified facts
What the public records show
CMS Open Payments records show Santsaran C Patel, MD received $383.73 in general payments during 2025 across 21 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 20.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $77.68 | 20.2% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $64.65 | 16.9% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $43.84 | 11.4% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $38.77 | 10.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $37.78 | 9.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.23 | 8.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $27.13 | 7.1% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.25 | 5.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.44 | 5.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.96 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $383.73 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $77.68 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $38.77 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $37.78 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $37.78 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $34.75 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $33.23 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.90 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.90 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $27.13 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $22.25 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.25 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $21.59 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.44 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 82 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 66 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
66 | 20 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
17 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
131 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
67 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
82 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 724 | 208 |
| Atorvastatin Calcium | Atorvastatin Calcium | 537 | 162 |
| Losartan Potassium | Losartan Potassium | 427 | 132 |
| Pantoprazole Sodium | Pantoprazole Sodium | 427 | 127 |
| Gabapentin | Gabapentin | 424 | 121 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 383 | 121 |
| Escitalopram Oxalate | Escitalopram Oxalate | 292 | 82 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 284 | 49 |
| Simvastatin | Simvastatin | 281 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 279 | 79 |
| Tramadol Hcl | Tramadol Hcl | 262 | 54 |
| Metformin Hcl | Metformin Hcl | 254 | 67 |
| Furosemide | Furosemide | 245 | 80 |
| Omeprazole | Omeprazole | 234 | 67 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 218 | 41 |
| Potassium Chloride | Potassium Chloride | 196 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 192 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 180 | 58 |
| Carvedilol | Carvedilol | 175 | 51 |
| Lisinopril | Lisinopril | 169 | 57 |
| Eliquis | Apixaban | 168 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 149 | 44 |
| Memantine Hcl | Memantine Hcl | 144 | 36 |
| Alprazolam | Alprazolam | 140 | 48 |
| Diclofenac Sodium | Diclofenac Sodium | 135 | 54 |
| Jardiance | Empagliflozin | 131 | 27 |
| Oxycodone Hcl | Oxycodone Hcl | 123 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 123 | 39 |
| Allopurinol | Allopurinol | 122 | 36 |
| Celecoxib | Celecoxib | 120 | 45 |
| Metformin Hcl Er | Metformin Hcl | 120 | 32 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 113 | 32 |
| Spironolactone | Spironolactone | 110 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 109 | 37 |
| Methylprednisolone | Methylprednisolone | 108 | 96 |
| Clopidogrel | Clopidogrel Bisulfate | 107 | 33 |
| Lorazepam | Lorazepam | 107 | 27 |
| Fenofibrate | Fenofibrate | 106 | 34 |
| Valacyclovir | Valacyclovir Hcl | 106 | 61 |
| Trazodone Hcl | Trazodone Hcl | 101 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 30 |
| Morphine Sulfate Er | Morphine Sulfate | 99 | suppressed |
| Ezetimibe | Ezetimibe | 98 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 93 | 34 |
| Meloxicam | Meloxicam | 90 | 28 |
| Montelukast Sodium | Montelukast Sodium | 89 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 87 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 28 |
| Famotidine | Famotidine | 85 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 84 | 22 |
| Levofloxacin | Levofloxacin | 82 | 77 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 82 | 25 |
| Ozempic | Semaglutide | 82 | 28 |
| Prednisone | Prednisone | 78 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 76 | 20 |
| Azithromycin | Azithromycin | 74 | 60 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 74 | 29 |
| Donepezil Hcl | Donepezil Hcl | 74 | 23 |
| Eszopiclone | Eszopiclone | 69 | 25 |
| Midodrine Hcl | Midodrine Hcl | 69 | 18 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 68 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 68 | 20 |
| Trulicity | Dulaglutide | 67 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | 16 |
| Synthroid | Levothyroxine Sodium | 66 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 65 | 19 |
| Atenolol | Atenolol | 64 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 64 | 18 |
| Baclofen | Baclofen | 63 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 63 | 17 |
| Glipizide Er | Glipizide | 62 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 61 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 56 | 16 |
| Venlafaxine Hcl | Venlafaxine Hcl | 56 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 38 |
| Methocarbamol | Methocarbamol | 53 | 23 |
| Diazepam | Diazepam | 52 | 22 |
| Levetiracetam | Levetiracetam | 52 | 11 |
| Pregabalin | Pregabalin | 51 | 13 |
| Glipizide | Glipizide | 50 | 12 |
| Fentanyl | Fentanyl | 48 | suppressed |
| Estradiol | Estradiol | 47 | 17 |
| Ibuprofen | Ibuprofen | 47 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | 17 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 45 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 14 |
| Lactated Ringers | Ringer's Solution,lactated | 44 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 44 | 14 |
| Morphine Sulfate | Morphine Sulfate | 43 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 41 | suppressed |
| Finasteride | Finasteride | 41 | 13 |
| Meclizine Hcl | Meclizine Hcl | 41 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 31 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 39 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | 11 |
| Valsartan | Valsartan | 39 | 11 |
| Glimepiride | Glimepiride | 38 | 12 |
| Lamotrigine | Lamotrigine | 38 | suppressed |
| Lovastatin | Lovastatin | 35 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 35 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 34 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | 12 |
| Xarelto | Rivaroxaban | 33 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 26 |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 31 | 13 |
| Hydrocortisone | Hydrocortisone | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 14 |
| Liothyronine Sodium | Liothyronine Sodium | 31 | suppressed |
| Sucralfate | Sucralfate | 31 | 11 |
| Gemfibrozil | Gemfibrozil | 30 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | 11 |
| Repatha Sureclick | Evolocumab | 30 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 26 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Risperidone | Risperidone | 26 | suppressed |
| Fluconazole | Fluconazole | 25 | 20 |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 25 | suppressed |
| Lidocaine | Lidocaine | 24 | 13 |
| Sertraline Hcl | Sertraline Hcl | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | 11 |
| Calcitriol | Calcitriol | 23 | suppressed |
| Klor-Con 10 | Potassium Chloride | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 22 | suppressed |
| Metolazone | Metolazone | 22 | suppressed |
| Rivastigmine | Rivastigmine | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 21 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Cefdinir | Cefdinir | 20 | 20 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Methotrexate | Methotrexate Sodium | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Oxycontin | Oxycodone Hcl | 17 | suppressed |
| Prolia | Denosumab | 17 | 12 |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 16 | suppressed |
| Ofloxacin | Ofloxacin | 16 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 15 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Modafinil | Modafinil | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Praluent Pen | Alirocumab | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Fluorouracil | Fluorouracil | 12 | suppressed |
| Gattex | Teduglutide | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Humira(Cf) | Adalimumab | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $383.73 · 21 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | AIRSUPRA, CAPLYTA, EVENITY, FREESTYLE LIBRE 3, KISUNLA, OTEZLA, Ozempic, REPATHA, Rybelsus, SYNTHROID, VOQUEZNA, VRAYLAR, Veozah, XIFAXAN | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error